Allarity considers partnerships for the potential launch of cancer drug
![Steve Carchedi, CEO at Allarity Therapeutics | Photo: Allarity Therapeutics / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13593973.ece/ALTERNATES/schema-16_9/doc7j0vmtoknlvztvwbd4c.jpg)
After several years of preparation, one of Allarity Therapeutics’ biggest days came along shortly before Christmas, when the firm could submit for approval its drug, dovitinib, against kidney cancer to the US Food and Drug Administration (FDA).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.